Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis

Exclusion Criteria

• •Who have a history of allergy to vitamin D3 derivative preparations or a history of relevant drug hypersensitivity.
• •Who are pregnant or lactating.
• •Who have any renal or hepatic insufficiency, or clinically significant cardiac, renal or hepatic disease.
• •Who are not deemed eligible as determined by medical history, physical examination or clinical laboratory safety tests.
• •Who have clinically relevant history or presence of any disease or surgical history other than psoriasis which is likely to affect the conduct of the study.
• •Whose serum calcium levels exceed the upper limit of reference range
• •Who have used any investigational medicinal product and/or participated in any clinical study within 60 days of treatment.
• •Who have been treated with systemic therapy within 30days of treatment.
• •Who have treated with biologics within 5 half-lives of the biologics before the day of treatment
• •Who have been treated with topical therapy within 14days before the day of treatment.